🇺🇸 Immune Support in United States

FDA authorised Immune Support on 5 June 2024

Marketing authorisations

FDA — authorised 5 June 2024

Application: ANDA080694
Marketing authorisation holder: CHARTWELL MOLECULAR
Indication: Labeling
Status: approved

The FDA granted marketing authorisation to Immune Support, manufactured by Chartwell Molecular, on 5 June 2024. The application number for this approval is ANDA080694. The approved indication for Immune Support is listed in its labelling, but the specific indication is not reported in the available data.

Read official source →

FDA

Marketing authorisation holder: CHARTWELL MOLECULAR
Status: approved

Immune Support in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Immunology approved in United States

Frequently asked questions

Is Immune Support approved in United States?

Yes. FDA authorised it on 5 June 2024; FDA has authorised it.

Who is the marketing authorisation holder for Immune Support in United States?

CHARTWELL MOLECULAR holds the US marketing authorisation.